Take a look at the day-by-day agenda or discover more with the buttons below.
We are updating this page regularly, so please check back soon for more information.
Day 1 – Wednesday 17th October
The Scientific Frontiers poster session presents the latest state-of-the-art developments in all aspects of prebiotic, probiotic and microbiome science relevant to health, wellbeing, consumers and industry. Posters will be selected based on abstracts submitted and reviewed by our Scientific Committee.
Day 2 – Thursday 18th October
Regulations Global IPA
George Paraskevakos, Executive Director, International Probiotics Association (IPA)
Current regulations on probiotic ingredients in ASEAN countries
Wai Mun Poon, Regulatory Affairs Consultant, Wong SJ Asia
Extended networking and poster viewing
Roundtable lunches – discuss the issues that matter most to you
Emerging and Future Opportunities for Modifying Gut Microbial Populations
Dr Michael Conlon, Senior Research Scientist, CSIRO Health & Biosecurity
Academics and consumers alike now recognise the important role that gut microbes play in human health. As a result, demand for probiotic and prebiotic products is growing fast. As the market accelerates, there are opportunities to broaden the range and effectiveness of new products that use or modulate gut microbes for health benefits. Michael examines the market opportunity and the science that will unlock it.
- The as yet uncharacterised adult gut microbes that are proving to be likely new targets for probiotic and prebiotic innovations
- New evidence that dietary polyphenols can beneficially modulate gut microbes
- Faecal microbial transplantation and microencapsulation – new delivery technologies that are now proving their worth
Sensing the gut’s state of health. The ingestible device that’s set to transform gut health monitoring and diagnosis
Kourosh Kalantar-zadeh, Professor, School of Chemical Engineering, University of New South Wales, Australia
Ingestible sensors have been hailed as the next big thing in human health monitoring and diagnostics. Among the first is a low-cost human gas sensing capsule developed by Kourosh and his team to diagnose gastrointestinal disorders and assess the impact of diet on the gut. The electronic capsule, which consists of gas sensors, micro-electronic circuits, tiny batteries and telecommunication components, does its work and then leaves the body naturally after passing through the gut. This presentation summarises the results of animal and human trials and assesses the market potential for this breakthrough device.
- What the capsule can tell us – from the concentration of the gut’s natural gases to internal temperature, and how the information can be used in diagnosis
- Discovering the unknown – immune system performance and the role of oxygen in the colon
- Transferring information – from the gut to the smartphone, how data is collected and verified
- Market ready? What animal and human tests tell us and how soon the capsule will be market-ready
Chair: Gary Scattergood, Editor-in-Chief, NutraIngredients-Asia
Probiota Asia Reception
Day 3 – Friday 19th October
Probiotic futures: A global analysis of current clinical trials and what they mean for the industry
Ger Rijkers, Professor of Biomedical and Life Sciences, University College Roosevelt, the Netherlands
On behalf of the IPA, Ger and his team have completed a comprehensive review of over 1,000 probiotics related clinical trials currently underway worldwide (as registered in www.clinical trials.gov). This gives the industry its first global snapshot of what’s happening in the world of probiotics; the scientific discoveries we can expect to see over the next five years and the product development opportunities they will give rise to. To complete the review, he has interrogated data from the US National Institute of Health and the World Health Organisation (WHO), making this the most both exhaustive and reliable information source available. Studies from countries like Japan, Australia and Iran are mainly posted on the WHO website. He will reveal:
- What’s happening where – and why Europe has emerged as a global hot spot for probiotic research and innovation
- What’s coming next – neurodegenerative diseases such as Parkinsons and Alzheimers heads the list of treatment areas currently under scrutiny
- What’s in it for you – implications for your product development pipeline and why you need to engage with the research now
Probiotics and mood: Reasons for optimism in depression cases
Dr Ng Qin Xiang
Generally safe and palatable, probiotics have garnered significant attention in recent years for their purported role in bi-directional signaling between the brain and the gut. It is purported that mood states alter gut function while gut health may influence mood and brain function. Xiang’s team at the Singapore Medical Association has undertaken a systematic review and meta-analysis of this subject, which reveals that probiotics can deliver positive benefits for people suffering from depression. In his presentation he reveals the details of the research, what it might mean for the treatment of depression, and the next steps to developing treatments.
- Passing signals – a summary of recent research into the gut-brain axis
- Reasons to be cheerful – how Xiang’s trial has proven the positive benefits of probiotics in depression cases
- Cure not prevention – how probiotics impact the mood state of the general population
- Towards a treatment – what we need to know in order to develop treatments that work in isolation or combined with other anti-depressant regimen
Scientific Frontiers session
The author of our highest rated Scientific Frontiers abstract – selected by our Scientific Committee – presents key findings and impacts of their research.